Fan, Huijie
Li, Yanrong
Sun, Mengying
Xiao, Wushuai
Song, Lijuan
Wang, Qing
Zhang, Bo
Yu, Jiezhong
Jin, Xiaoming
Ma, Cungen
Chai, Zhi
Funding for this research was provided by:
National Natural Science Foundation of China ([No. 81703978])
Key Research and Development (R&D) Projects of Shanxi Province ([Nos. 201803D31091, 201803D31209])
Outstanding Youth Talents Program of Shanxi Province ([[2019]35])
Natural Science Foundation of Shanxi Province ([201901D111334])
International Science and Technology Cooperation Project of Shanxi Province ([No. 201703D421016])
Key Research Project Supported by Shanxi Scholarship Council ([Nos. 2014-7, 2017-129])
Shanxi university Science and technology innovation Project ([2019L0724])
Scientific and technological innovation team of integrated Chinese and Western medicine for the prevention and treatment on nervous system diseases of Shanxi University of Chinese medicine ([No. 2018TD-012])
Article History
Received: 17 November 2020
Revised: 7 July 2021
Accepted: 17 July 2021
First Online: 20 August 2021
Declarations
:
: The authors declare no conflicts of interest.
: Animal assays were permitted by the Ethical Committee of Experimental Animals of Academic Committee of Shanxi University of Traditional Chinese Medicine (AP202004018), and performed in accordance with the guidelines of the China Council on Animal Care and Use. All rats were bred in a SPF-level animal center under standard laboratory conditions.
: Hyperoside (PHL89227, ≥ 95.0%) was purchased from Phyproof Company (Germany). Rotenone (R8875, ≥ 95.0%) was purchased from Sigma-Aldrich (USA). Specific pathogen-free (SPF) male Sprague–Dawley (SD) rats (240–260 g) were purchased from Jiangsu Ailingfei Biotechnology Co. LTD (China).
: Not applicable.